Clinical trials: Neoplasm, Experimental
68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.
BIOPSTAGE is a prospective, non-randomized, diagnostic, multi-cohort investigational study to evaluate the impact of pelvic Multi-parametric 3-Tesla magnetic resonance imaging (mp-3TMRI) and whole-body 68Ga-PSMA PET/CT for…
- Conditions
- 68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer, TNM Staging
- Trial name
- BIOPSTAGE (NCT03465579)
- Testing
- pelvic MRI, 68Ga-PSMA PET/CT
- Where
- 2 sites in Italy
- Volunteers
- 261 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Hepatoma, Liver Neoplasms
Sorafenib and TRC105 in Hepatocellular Cancer
Background: Sorafenib is a drug that has been approved to treat kidney and liver cancer (hepatocellular carcinoma, or HCC) and has been shown to prolong survival in patients with HCC.
- Conditions
- Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular
- Trial name
- NCT01306058
- Testing
- TRC 105, Sorafenib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm
Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors
This clinical trial studies multi-tracer positron emission tomography in patients with solid tumors. Diagnostic procedures, such as multi-tracer positron emission tomography, may help measure a patient's response to treatment.
- Trial name
- NCT01243333
- Testing
- [F-18]fluorodeoxyglucose, [F-18]fluorothymidine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Hematologic Malignancies
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
The purpose of this research study is to determine if an experimental agent, LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood (hematopoietic) stem cell transplantation
- Trial name
- NCT00429416
- Testing
- L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Gastrointestinal Stromal Tumors
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Patients with metastatic or locally advanced gastrointestinal stromal tumors (GIST) who develop resistance against the two hitherto approved drugs for this disease, the tyrosin kinase inhibitors (TKIs) imatinib and sunitinib…
- Trial name
- PAGIST (NCT01524848)
- Testing
- Pazopanib
- Where
- 16 sites in Denmark, Finland and 3 more
- Volunteers
- 72 people
- Sponsor
- Scandinavian Sarcoma Group
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumors
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
This trial is a first-in-human, multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KY-0301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT06928363
- Testing
- KY-0301
- Volunteers
- 212 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Breast Self-Examination, Breast Cancer
Experimental Study With Pretest/Posttest Groups Which the Intervention Group Have the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day
H0: Among the intervention and control groups of reminder notifications relating to self-examination H01: Average breast cancer fear score and H02: There is no difference in the average score of breast cancer health beliefs.
- Conditions
- Breast Self-Examination, Breast Cancer, Nursing Caries, Cancer
- Trial name
- BreastSelfExam (NCT05995483)
- Testing
- Early Diagnosis on BSE
- Where
- Cyprus
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Eastern Mediterranean University
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT05909904
- Testing
- Tislelizumab, BGB-A425, LBL-007
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 160 people
- Sponsor
- BeiGene
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Pancreatic Cancer
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer
This is a multicenter, open-label, Phase II umbrella study conducted in participants with advanced or metastatic pancreatic cancer.
- Trial name
- NCT07814066
- Testing
- SKB571
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Breast Cancer
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
The randomized LITE study will compare liposomal doxorubin versus standard epirubicin in the treatment of female breast cancer. In order to detect as early as possible post-chemotherapy cardiotoxicity, tissue Doppler imaging…
- Trial name
- LITE (NCT00531973)
- Testing
- liposomal doxorubicin, epirubicin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Catholic University, Italy
Advanced Cancers
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
The goal of this clinical research study is to find out if using the tracer (liquid used in imaging scans) [18F]fluciclatide in positron emission tomography / computed tomography (PET/CT) scans will help researchers learn more…
- Trial name
- NCT02193672
- Testing
- [18F] Fluciclatide, PET/CT Scan, Phone Calls
- Sponsor
- M.D. Anderson Cancer Center
Self Efficacy, Neoplasms (Cancer / Tumors)
Identifying and Mobilizing Personal Resources to Improve Well-Being in Cancer Participants Using the CAERES Protocol
Cancer patients often experience emotional distress, fatigue, and reduced quality of life that may not be fully addressed by medical treatment alone.
- Conditions
- Self Efficacy, Neoplasms (Cancer / Tumors), Cancer-related Fatigue, Post-Traumatic Growth, Psychological
- Trial name
- CAERES (NCT07582666)
- Testing
- CAERES (Cancer Auto-Evaluation of RESources) Psychosocial Intervention
- Where
- 3 sites in Switzerland
- Volunteers
- 32 people
- Sponsor
- UniDistance Suisse
Colorectal Cancer
Precision-Based Magnesium Trial
Colorectal cancer is the fourth most common incident cancer and the second most common cause of cancer death in the United States, with approximately 150,000 new cases and 57,000 deaths per year.
- Trial name
- NCT01105169
- Testing
- Magnesium glycinate
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Wound Heal
Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.
A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs…
- Trial name
- MOSAIC (NCT06600152)
- Testing
- MAP Wound Matrix, DuoDerm
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tempo Therapeutics